A new class of startups is scouting for deals - on both sides of the Pacific

It used to be that executing a global strategy meant finding a partner for the European market. Now, China has completely changed the way the world works. Startups have been in-licensing for years in a growing set of diseases. And now they are outlicensing to the US and Europe. What happens as more sophisticated R&D organizations go after novel drug targets? Lets find out.

01:02:00